Alimera Sciences files $75M IPO

Alimera Sciences is braving a badly roiled public market with plans to push a $75 million IPO. The Atlanta-based biotech is developing ophthalmic drugs. Credit Suisse, Citi, Cowen and Co. and Leerink Swann are underwriting the IPO. Alimera has raised more than $71 million from a group of venture capital groups that include Scale Venture Partners, Domain Associates, Intersouth Partners and Polaris Venture Partners. In addition to developing new therapies, Alimera also markets OTC ophthalmic products. Report

Suggested Articles

Levo Therapeutics’ lead program did not beat placebo in a phase 3 study of Prader-Willi syndrome, a genetic disorder that causes insatiable hunger.

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.